Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine + cisplatin as neoadjuvant, followed by durvalumab adjuvant, in muscle-invasive bladder cancer
2018-001811-59Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by AstraZeneca. Primary endpoint: pCR. Started Oct 2018; status: active.
02
Drugs
durvalumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2018-001811-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001811-59.